This Article Abstract Full Text Full Text (PDF) View Online Only Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (98) Citing Articles via Google Scholar Google Scholar Articles by Galié, N. Articles by Rubin, L. J. Search for Related Content PubMed PubMed Citation Articles by Galié, N. Articles by Rubin, L. J.

Ambrisentan Therapy for Pulmonary Arterial Hypertension

Nazzareno Galié, MD^_*,_*, David Badesch, MD, Ronald Oudiz, MD, Gérald Simonneau, MD, Michael D. McGoon, MD^||, Anne M. Keogh, MD^¶, Adaani E. Frost, MD^#, Diane Zwicke, MD^_**, Robert Naeije, MD, Shelley Shapiro, MD, PhD, Horst Olschewski, MD and Lewis J. Rubin, MD^||||

^_* University of Bologna, Bologna, Italy
University of Colorado Health Science Center, Denver, Colorado
Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California
Hôpital Antoine Béclère, Clamart, France
^|| Mayo Clinic College of Medicine, Rochester, Minnesota
^¶ Saint Vincent’s Hospital, Darlinghurst, Australia
^# Baylor College of Medicine and the Methodist Hospital, Houston, Texas
^_** St. Luke’s/Aurora Sinai Medical Centers, University of Wisconsin Medical School-Milwaukee Clinical Campus, Milwaukee, Wisconsin
Erasmus University, Brussels, Belgium
University of Southern California, Keck School of Medicine, Los Angeles, California
University Giessen Lung Center, Giessen, Germany
^|||| University of California-San Diego, San Diego, California

View larger version (19K): [in a new window]   Figure 1 The study design. Subjects randomized to the 5-mg dose group received 2.5 mg for 2 weeks and 5 mg for 10 weeks. Subjects randomized to the 10-mg dose group received 2.5 mg for 2 weeks, 5 mg for 2 weeks, and 10 mg for 8 weeks. Dose adjustments were allowed during the optional open-label extension period (weeks 13 to 24).

View larger version (23K): [in a new window]   Figure 2 (A) Mean change from baseline in 6-min walk distance (6MWD) for all patients at week 12 for the 1-, 2.5-, 5-, and 10-mg-dose groups and for all dose groups combined. (B) Mean change from baseline in 6MWD for idiopathic pulmonary arterial hypertension patients at week 12 for the 1-, 2.5-, 5-, and 10-mg-dose groups and for all dose groups combined. (C) Mean change from baseline in 6MWD for patients with pulmonary arterial hypertension associated with collagen vascular disease, anorexigen use, or human immunodeficiency virus infection at week 12 for the 1-, 2.5-, 5-, and 10-mg-dose groups and for all dose groups combined. *p < 0.02, p < 0.001, p < 0.03.

View larger version (13K): [in a new window]   Figure 3 Mean change from baseline in 6-min walk distance (6MWD) for all dose group combined (n = 64) up to 24 weeks. Error bars indicate standard error of the mean. *p < 0.001.

View larger version (34K): [in a new window]   Figure 4 Change from baseline in World Health Organization functional class for all dose groups combined of ambrisentan up to 24 weeks. Higher classes indicate a greater severity of disease. Black bars = class I; ruled bars = class II; open bars = class III.